Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
In the ever-evolving landscape of cancer treatment, tumor-infiltrating lymphocyte (TIL) therapy stands out as a promising avenue for solid tumor immunotherapy. Leveraging advanced cellular immunotherapy techniques, TIL therapy involves isolating, expanding, and reintroducing a patient's immune cells to combat cancer. However, optimizing its efficacy requires innovative combination strategies, integrating various therapeutic modalities to overcome intrinsic challenges like immunosuppression within the tumor microenvironment.
Fig.1 TIL therapy combined with other therapies.1,2
Creative Biolabs has positioned itself at the forefront of TIL therapy innovation. Our methodologies encapsulate a multidisciplinary approach, ensuring precise customization of therapy strategies.
Checkpoint inhibitors represent a breakthrough in oncology, enhancing the body’s immune response to tumors. Integrating checkpoint inhibitors with TIL therapy can potentiate immune activity against cancer cells. These inhibitors, such as those targeting PD-1/PD-L1 or CTLA-4 pathways, release the “brakes” on the immune system imposed by tumor-expressed checkpoint ligands. Creative Biolabs’ approach involves the strategic sequencing and combination of TIL infusion with checkpoint blockade to amplify therapeutic outcomes.
Traditional chemotherapy remains a cornerstone of cancer treatment, primarily targeting rapidly dividing cancerous cells but often affecting normal, healthy cells as well. In our strategy, specific chemotherapeutics are used in sub-lethal doses to modify the tumor microenvironment and enhance the infiltration and activity of TILs. Agents such as cyclophosphamide can deplete regulatory T cells within the tumor, mitigating the immunosuppressive milieu and promoting a more hospitable environment for TILs. Creative Biolabs carefully tailors chemotherapy regimens to complement TIL therapy, thus overcoming resistance factors and optimizing the overall antitumor response.
Creative Biolabs offers a comprehensive suite of services tailored to advance TIL therapy development. Our package includes:
Q1: What are the main advantages of combining TIL therapy with checkpoint inhibitors?
A1: Checkpoint inhibitors prevent the exhaustion of TILs, enhancing their ability to attack and destroy tumor cells. Combining these inhibitors with TIL therapy can lead to improved patient outcomes by overcoming immune suppression within tumors.
Q2: How does chemotherapy contribute to the success of TIL therapy?
A2: Chemotherapy can induce the release of tumor antigens, facilitating a more robust immune response by TILs. This immunogenic effect primes the immune system to recognize and mount an effective attack against tumor cells, aiding TIL therapy success.
Creative Biolabs' commitment to pioneering combination therapies for TIL development underscores its dedication to transforming cancer treatment paradigms, driving progress with precision science and patient-centric innovation.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
